Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)

Clinical Trial ID NCT01673867

PubWeight™ 72.49‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01673867

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015 12.54
2 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 9.86
3 Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013 4.78
4 Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2015 4.68
5 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
6 Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2013 2.64
7 The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol 2015 2.13
8 Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol 2015 1.45
9 Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013 1.41
10 Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014 1.35
11 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
12 Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 2015 1.23
13 Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 2015 1.21
14 Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep 2015 1.18
15 Antibodies to watch in 2014. MAbs 2013 1.14
16 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
17 New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 2015 1.12
18 A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 2013 1.12
19 Targeted therapies in development for non-small cell lung cancer. J Carcinog 2013 1.12
20 The evolving genomic classification of lung cancer. J Pathol 2014 1.08
21 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
22 Immune checkpoint inhibitors in clinical trials. Chin J Cancer 2014 0.98
23 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
24 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
25 New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res 2014 0.94
26 Immunotherapy for Lung Cancer: Has it Finally Arrived? Front Oncol 2014 0.94
27 Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol 2016 0.89
28 New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2015 0.89
29 Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol 2015 0.87
30 Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol 2013 0.87
31 Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol 2014 0.85
32 Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy? Transl Lung Cancer Res 2014 0.83
33 Current progress in immunotherapy for pancreatic cancer. Cancer Lett 2015 0.83
34 Immunotherapy in lung cancer. Transl Lung Cancer Res 2014 0.82
35 The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist 2015 0.81
36 What lies within: novel strategies in immunotherapy for non-small cell lung cancer. Oncologist 2013 0.81
37 Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. Med Oncol 2014 0.80
38 Immunotherapy in lung cancer. Transl Lung Cancer Res 2014 0.80
39 New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics 2016 0.79
40 PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. Onco Targets Ther 2016 0.78
41 Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res 2014 0.78
42 Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology 2015 0.77
43 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
44 Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets. Nat Rev Clin Oncol 2015 0.76
45 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
46 Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol 2014 0.75
47 Prime time for immune-checkpoint targeted therapy at ASCO 2015. Oncoimmunology 2015 0.75
48 Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer? Transl Lung Cancer Res 2016 0.75
Next 100